NO319166B1 - Anvendelse av olanzapin i kombinasjon med fluoxetin og et farmasoytisk preparat omfattende denne kombinasjon. - Google Patents

Anvendelse av olanzapin i kombinasjon med fluoxetin og et farmasoytisk preparat omfattende denne kombinasjon. Download PDF

Info

Publication number: NO319166B1
Authority: NO; Norway
Prior art keywords: use according; patient suffers; olanzapine; fluoxetine; susceptible
Prior art date: 1996-09-23

Application number

NO19991381A

Other languages

English (en)

Norwegian (no)

Other versions

NO991381D0 (no

NO991381L (no

Inventor

Franklin Porter Bymaster

Kenneth Wayne Perry

Gary Dennis Tollefson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1999-03-22

Publication date

2005-06-27

1999-03-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-03-22 Publication of NO991381D0 publication Critical patent/NO991381D0/no

1999-03-22 Publication of NO991381L publication Critical patent/NO991381L/no

2005-06-27 Publication of NO319166B1 publication Critical patent/NO319166B1/no

Links

KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims description 28
229960005017 olanzapine Drugs 0.000 title claims description 27
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 title claims description 19
229960002464 fluoxetine Drugs 0.000 title claims description 19
239000008194 pharmaceutical composition Substances 0.000 title description 6
208000028017 Psychotic disease Diseases 0.000 claims description 35
238000002360 preparation method Methods 0.000 claims description 26
239000000126 substance Substances 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
201000000980 schizophrenia Diseases 0.000 claims description 8
206010026749 Mania Diseases 0.000 claims description 7
208000020401 Depressive disease Diseases 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
239000000164 antipsychotic agent Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
-1 dexmethasone Chemical compound 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
208000019901 Anxiety disease Diseases 0.000 claims description 4
239000002249 anxiolytic agent Substances 0.000 claims description 4
230000000949 anxiolytic effect Effects 0.000 claims description 4
229940005530 anxiolytics Drugs 0.000 claims description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
239000003326 hypnotic agent Substances 0.000 claims description 4
230000000147 hypnotic effect Effects 0.000 claims description 4
239000000932 sedative agent Substances 0.000 claims description 4
229940125723 sedative agent Drugs 0.000 claims description 4
201000009032 substance abuse Diseases 0.000 claims description 4
208000020925 Bipolar disease Diseases 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
206010014418 Electrolyte imbalance Diseases 0.000 claims description 2
206010051283 Fluid imbalance Diseases 0.000 claims description 2
206010019196 Head injury Diseases 0.000 claims description 2
208000036626 Mental retardation Diseases 0.000 claims description 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
230000016571 aggressive behavior Effects 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims description 2
229960003920 cocaine Drugs 0.000 claims description 2
230000002124 endocrine Effects 0.000 claims description 2
239000012530 fluid Substances 0.000 claims description 2
239000000380 hallucinogen Substances 0.000 claims description 2
230000002440 hepatic effect Effects 0.000 claims description 2
208000017169 kidney disease Diseases 0.000 claims description 2
208000019423 liver disease Diseases 0.000 claims description 2
230000002503 metabolic effect Effects 0.000 claims description 2
229960001344 methylphenidate Drugs 0.000 claims description 2
230000000926 neurological effect Effects 0.000 claims description 2
229940005483 opioid analgesics Drugs 0.000 claims description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 2
229950010883 phencyclidine Drugs 0.000 claims description 2
230000000698 schizophrenic effect Effects 0.000 claims description 2
231100000736 substance abuse Toxicity 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical group Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims 4
229960000389 fluoxetine hydrochloride Drugs 0.000 claims 4
208000022610 schizoaffective disease Diseases 0.000 claims 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
208000009810 Catatonic Schizophrenia Diseases 0.000 claims 1
208000001495 Disorganized Schizophrenia Diseases 0.000 claims 1
208000036754 Schizophrenia, catatonic type Diseases 0.000 claims 1
208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
208000036750 Schizophrenia, residual type Diseases 0.000 claims 1
229940025084 amphetamine Drugs 0.000 claims 1
230000003001 depressive effect Effects 0.000 claims 1
208000024714 major depressive disease Diseases 0.000 claims 1
240000004308 marijuana Species 0.000 claims 1
208000002851 paranoid schizophrenia Diseases 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 19
238000000034 method Methods 0.000 abstract description 7
230000000561 anti-psychotic effect Effects 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 37
239000003814 drug Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 12
150000003839 salts Chemical class 0.000 description 11
239000003826 tablet Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000003693 atypical antipsychotic agent Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000002253 acid Substances 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
229940127236 atypical antipsychotics Drugs 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960004170 clozapine Drugs 0.000 description 3
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
239000003772 serotonin uptake inhibitor Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000020186 Schizophreniform disease Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
239000002131 composite material Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
238000001690 micro-dialysis Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
235000020030 perry Nutrition 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
230000008569 process Effects 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000207199 Citrus Species 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000027776 Extrapyramidal disease Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
QXFHPLPMTXEJPV-UHFFFAOYSA-N octane-1-sulfonic acid;sodium Chemical compound [Na].CCCCCCCCS(O)(=O)=O QXFHPLPMTXEJPV-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960002888 oxitriptan Drugs 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000012066 reaction slurry Substances 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO19991381A 1996-09-23 1999-03-22 Anvendelse av olanzapin i kombinasjon med fluoxetin og et farmasoytisk preparat omfattende denne kombinasjon. NO319166B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2688496P	1996-09-23	1996-09-23
PCT/US1997/015874 WO1998011897A1 (en)	1996-09-23	1997-09-09	Combination therapy for treatment of psychoses

Publications (3)

Publication Number	Publication Date
NO991381D0 NO991381D0 (no)	1999-03-22
NO991381L NO991381L (no)	1999-03-22
NO319166B1 true NO319166B1 (no)	2005-06-27

Family

ID=21834363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991381A NO319166B1 (no)	1996-09-23	1999-03-22	Anvendelse av olanzapin i kombinasjon med fluoxetin og et farmasoytisk preparat omfattende denne kombinasjon.

Country Status (29)

Country	Link
US (1)	US6147072A (pt)
EP (1)	EP0830864B9 (pt)
JP (1)	JP2001503031A (pt)
KR (1)	KR100532901B1 (pt)
CN (1)	CN1162156C (pt)
AR (1)	AR008462A1 (pt)
AT (1)	ATE231724T1 (pt)
AU (1)	AU719033C (pt)
BR (1)	BR9711530A (pt)
CA (1)	CA2264941C (pt)
CO (1)	CO4900058A1 (pt)
CZ (1)	CZ301154B6 (pt)
DE (1)	DE69718731T2 (pt)
DK (1)	DK0830864T3 (pt)
EA (1)	EA001317B1 (pt)
EG (1)	EG24660A (pt)
ES (1)	ES2191152T3 (pt)
HU (1)	HU228178B1 (pt)
IL (2)	IL128730A0 (pt)
MY (1)	MY125564A (pt)
NO (1)	NO319166B1 (pt)
NZ (1)	NZ334168A (pt)
PE (1)	PE110198A1 (pt)
PL (1)	PL190374B1 (pt)
RS (1)	RS49828B (pt)
TW (1)	TW541178B (pt)
UA (1)	UA62937C2 (pt)
WO (1)	WO1998011897A1 (pt)
ZA (1)	ZA977967B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT901786E (pt)	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ES2292238T3 (es) *	1998-04-24	2008-03-01	Scarista Limited	Tratamiento de la depresion y preparaciones farmaceuticas para el mismo.
WO1999061027A1 (en) *	1998-05-22	1999-12-02	Eli Lilly And Company	Combination therapy for treatment of refractory depression
US6960577B2 (en)	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
AU756468B2 (en) *	1998-05-29	2003-01-16	Eli Lilly And Company	Combination therapy for treatment of bipolar disorders
WO2000024399A1 (en) *	1998-10-23	2000-05-04	Sepracor Inc.	Compositions and methods employing r(-) fluoxetine and other active ingredients
EP1133299A1 (en) *	1998-11-23	2001-09-19	Sepracor Inc.	2-hydroxymethylolanzapine compositions and methods
EP1027885B1 (en) *	1999-02-09	2008-07-09	Pfizer Products Inc.	Basic drug compositions with enhanced bioavailability
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
DE50011819D1 (de)	1999-03-12	2006-01-12	Aesica Pharmaceuticals Ltd	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
JP2002544223A (ja) *	1999-05-12	2002-12-24	ソルベイ・フアーマシユーチカルズ・ベー・ブイ	精神病性障害の治療方法
AU4598400A (en) *	1999-05-19	2000-12-12	Astrazeneca Ab	Method of treatment
AU4973800A (en) *	1999-06-09	2000-12-28	Eli Lilly And Company	Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
EP1220658A1 (en) *	1999-09-28	2002-07-10	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
JP2003517481A (ja)	1999-12-17	2003-05-27	ブリストルーマイヤーズスクイブカンパニー	抗精神病複素環式化合物
TR200201617T2 (tr)	1999-12-23	2002-10-21	Pfizer Products Inc.	Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
US6572890B2 (en)	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
JP2004502655A (ja) *	2000-06-30	2004-01-29	イーライ・リリー・アンド・カンパニー	精神病の処置のための組み合わせ療法
US7666445B2 (en) *	2000-10-20	2010-02-23	The Trustees Of The University Of Pennsylvania	Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) *	2000-10-27	2003-12-18	H. Lundbeck A/S	Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) *	2000-12-05	2002-06-05	Phillip Branch Chappell	Combination treatment for depression, anxiety and psychosis
MXPA03006003A (es) *	2001-01-02	2005-09-08	Upjohn Co	Nuevas combinaciones de farmacos.
WO2002062346A1 (en) *	2001-02-06	2002-08-15	Astrazeneca Ab	Method of treating substance abuse with quetiapine
US20020123490A1 (en) *	2001-03-01	2002-09-05	Pfizer Inc.	Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
MEP5908A (xx) *	2001-05-01	2010-02-10	Lundbeck & Co As H	Upotreba enantiomerno čistog escitaloprama
US7034059B2 (en)	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
MXPA05000294A (es) *	2002-07-30	2005-08-19	Peter Migaly	Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US20070077301A1 (en) *	2002-12-23	2007-04-05	Meyer Glenn A	Venlafaxine osmotic device formulation
EP1723957A3 (en)	2002-12-27	2013-01-23	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es)	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CA2525323A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Method for enhancing cognition using ziprasidone
MXPA05012392A (es) *	2003-05-16	2006-02-02	Pfizer Prod Inc	Tratamientos de ansiedad con ziprasidona.
CA2525866A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Treatment of psychotic and depressive disorders
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
US20050032781A1 (en) *	2003-08-06	2005-02-10	Elliot Ehrich	Methods for administering active agents to CYP 2D6 sensitive patients
EP1547650A1 (en) *	2003-12-02	2005-06-29	B & B Beheer NV	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1713486A4 (en) *	2003-12-02	2009-04-29	Sheldon Leslie James	COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
US7855195B2 (en)	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en)	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en)	2003-12-02	2010-04-21	PharmaNeuroBoost N.V.	Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
JP2007516292A (ja) *	2003-12-23	2007-06-21	ダーファーマ，インコーポレイテッド	ドーパミン受容体結合化合物の共投与
US8221778B2 (en)	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
CA2553254C (en) *	2004-01-12	2013-12-17	The Trustees Of The University Of Pennsylvania	Long-term delivery formulations and methods of use thereof
US20050171088A1 (en) *	2004-01-30	2005-08-04	Astrazeneca Ab	Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006027800A1 (en) *	2004-09-06	2006-03-16	Shasun Chemicals And Drugs Limited	A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
WO2006083204A1 (en) *	2004-12-27	2006-08-10	Alpha 2 Pharmaceutical Ab	Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
CZ297214B6 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) *	2005-09-08	2012-02-10	Х. Луннбэк А/С	Стійкі тверді склади сертиндолу
US20070093471A1 (en) *	2005-10-26	2007-04-26	Alamo Pharmaceuticals, Llc	Compositions and methods for the administration clozapine formulations which modulate body weight
US9095519B2 (en) *	2007-02-09	2015-08-04	Alphapharm Pty Ltd	Dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008122019A1 (en) *	2007-04-02	2008-10-09	Cypress Biosciences, Inc.	Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US8198305B2 (en) *	2007-04-13	2012-06-12	Concert Pharmaceuticals Inc.	1,2-benzisoxazol-3-yl compounds
RU2508106C2 (ru) *	2007-08-01	2014-02-27	Сергей Олегович Бачурин	Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2508096C2 (ru) *	2007-08-01	2014-02-27	Сергей Олегович Бачурин	Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
HRP20171908T1 (hr) *	2007-08-03	2018-01-26	Richter Gedeon Nyrt.	Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
CA2712282A1 (en) *	2008-01-25	2009-07-30	Alphapharm Pty Ltd	Delayed release pharmaceutical composition of duloxetine
WO2011018801A2 (en) *	2009-08-12	2011-02-17	Genepharm India Pvt Ltd	Solid oral dosage form of ziprasidone
WO2011057176A1 (en)	2009-11-06	2011-05-12	Forest Laboratories Holding Limited	Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
WO2015089494A1 (en) *	2013-12-13	2015-06-18	Ankenman Ralph	Compositions and methods for treating dysregulated systems
RU2021128797A (ru)	2014-02-07	2021-11-26	Ньюрокрайн Байосайенсиз, Инк.	Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
MX381258B (es)	2015-10-30	2025-03-12	Neurocrine Biosciences Inc	Sales de valbenazina y polimorfos de las mismas.
US10160757B2 (en)	2015-12-23	2018-12-25	Neuroscrine Biosciences, Inc.	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10336679B2 (en) *	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
EA201991786A1 (ru)	2017-01-27	2020-01-16	Нейрокрин Байосайенсиз, Инк.	Способы введения некоторых vmat2-ингибиторов
IL301770B2 (en)	2017-09-21	2024-06-01	Neurocrine Biosciences Inc	High dose valbenazine formulation and related preparations, methods and kits
KR20250070134A (ko)	2017-10-10	2025-05-20	뉴로크린 바이오사이언시즈 인코퍼레이티드	특정 vmat2 억제제의 투여 방법
MY198713A (en)	2017-10-10	2023-09-19	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
SG11202100303QA (en)	2018-08-15	2021-02-25	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
CN108938635A (zh) *	2018-08-24	2018-12-07	山西医科大学第医院	一种低剂量非典型抗精神病药物组合物
CN108938645A (zh) *	2018-08-24	2018-12-07	山西医科大学第医院	一种抗精神病药物组合物
CN108926569A (zh) *	2018-08-24	2018-12-04	山西医科大学第医院	一种非典型抗精神病药物组合物
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) *	2019-12-31	2022-06-24	北京鑫开元医药科技有限公司	一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5605897A (en) *	1991-04-23	1997-02-25	Eli Lilly And Company	2-methyl-thieno-benzodiazepine
PL187926B1 (pl) *	1996-03-25	2004-11-30	Lilly Co Eli	Kompozycja farmaceutyczna do leczenia bólu
EP0906104A4 (en) *	1996-03-25	2003-12-10	Lilly Co Eli	PAIN TREATMENT PROCESS
US5846928A (en) *	1996-08-01	1998-12-08	Pasken Products Co., Ltd.	Method for treating cancer patients
US5877198A (en) *	1996-10-17	1999-03-02	Milkhaus Laboratory, Inc.	Treatment of urinary incontinence

1997
- 1997-09-04 ZA ZA977967A patent/ZA977967B/xx unknown
- 1997-09-09 CN CNB971981132A patent/CN1162156C/zh not_active Expired - Lifetime
- 1997-09-09 AU AU44112/97A patent/AU719033C/en not_active Expired
- 1997-09-09 IL IL12873097A patent/IL128730A0/xx not_active IP Right Cessation
- 1997-09-09 RS YUP-152/99A patent/RS49828B/sr unknown
- 1997-09-09 CZ CZ0098799A patent/CZ301154B6/cs not_active IP Right Cessation
- 1997-09-09 CA CA002264941A patent/CA2264941C/en not_active Expired - Lifetime
- 1997-09-09 KR KR10-1999-7002422A patent/KR100532901B1/ko not_active Expired - Lifetime
- 1997-09-09 BR BR9711530A patent/BR9711530A/pt active Search and Examination
- 1997-09-09 IL IL16183397A patent/IL161833A0/xx not_active IP Right Cessation
- 1997-09-09 HU HU9903905A patent/HU228178B1/hu unknown
- 1997-09-09 PL PL97332481A patent/PL190374B1/pl unknown
- 1997-09-09 JP JP10514717A patent/JP2001503031A/ja active Pending
- 1997-09-09 NZ NZ334168A patent/NZ334168A/xx not_active IP Right Cessation
- 1997-09-09 WO PCT/US1997/015874 patent/WO1998011897A1/en not_active Ceased
- 1997-09-09 UA UA99031565A patent/UA62937C2/uk unknown
- 1997-09-09 EA EA199900324A patent/EA001317B1/ru not_active IP Right Cessation
- 1997-09-12 TW TW086113280A patent/TW541178B/zh not_active IP Right Cessation
- 1997-09-16 MY MYPI97004299A patent/MY125564A/en unknown
- 1997-09-19 AR ARP970104324A patent/AR008462A1/es active IP Right Grant
- 1997-09-19 CO CO97054849A patent/CO4900058A1/es unknown
- 1997-09-19 PE PE1997000840A patent/PE110198A1/es not_active Application Discontinuation
- 1997-09-22 DE DE69718731T patent/DE69718731T2/de not_active Expired - Lifetime
- 1997-09-22 ES ES97307375T patent/ES2191152T3/es not_active Expired - Lifetime
- 1997-09-22 AT AT97307375T patent/ATE231724T1/de active
- 1997-09-22 DK DK97307375T patent/DK0830864T3/da active
- 1997-09-22 EP EP97307375A patent/EP0830864B9/en not_active Expired - Lifetime
- 1997-09-23 EG EG98197A patent/EG24660A/xx active
- 1997-09-23 US US08/935,872 patent/US6147072A/en not_active Expired - Lifetime
1999
- 1999-03-22 NO NO19991381A patent/NO319166B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA001317B1 (ru)	2001-02-26
ES2191152T3 (es)	2003-09-01
NO991381D0 (no)	1999-03-22
MY125564A (en)	2006-08-30
DE69718731D1 (de)	2003-03-06
YU15299A (sh)	2002-06-19
BR9711530A (pt)	1999-08-24
PE110198A1 (es)	1999-01-21
CO4900058A1 (es)	2000-03-27
ATE231724T1 (de)	2003-02-15
AU719033C (en)	2005-08-04
CN1230886A (zh)	1999-10-06
CZ301154B6 (cs)	2009-11-18
CZ98799A3 (cs)	1999-12-15
IL161833A0 (en)	2005-11-20
PL190374B1 (pl)	2005-12-30
KR20000048518A (ko)	2000-07-25
HUP9903905A2 (hu)	2000-10-28
DK0830864T3 (da)	2003-05-26
HUP9903905A3 (en)	2001-03-28
CN1162156C (zh)	2004-08-18
NO991381L (no)	1999-03-22
PL332481A1 (en)	1999-09-13
NZ334168A (en)	2000-09-29
IL128730A0 (en)	2000-01-31
EP0830864B9 (en)	2003-09-03
DE69718731T2 (de)	2003-09-11
CA2264941C (en)	2008-11-18
RS49828B (sr)	2008-08-07
US6147072A (en)	2000-11-14
TW541178B (en)	2003-07-11
CA2264941A1 (en)	1998-03-26
EP0830864B1 (en)	2003-01-29
ZA977967B (en)	1999-03-04
KR100532901B1 (ko)	2005-12-02
EP0830864A1 (en)	1998-03-25
EG24660A (en)	2010-04-07
EA199900324A1 (ru)	1999-08-26
AU4411297A (en)	1998-04-14
UA62937C2 (uk)	2004-01-15
JP2001503031A (ja)	2001-03-06
HU228178B1 (en)	2013-01-28
AU719033B2 (en)	2000-05-04
HK1009755A1 (en)	1999-06-11
WO1998011897A1 (en)	1998-03-26
AR008462A1 (es)	2000-01-19

Publication	Publication Date	Title
NO319166B1 (no)	2005-06-27	Anvendelse av olanzapin i kombinasjon med fluoxetin og et farmasoytisk preparat omfattende denne kombinasjon.
AU756468B2 (en)	2003-01-16	Combination therapy for treatment of bipolar disorders
AU761510B2 (en)	2003-06-05	Combination therapy for treatment of refractory depression
US20030027817A1 (en)	2003-02-06	Combination therapy for treatment of bipolar disorders
US6960577B2 (en)	2005-11-01	Combination therapy for treatment of refractory depression
CZ20012386A3 (cs)	2002-02-13	Antagonisté 5HT pro antidepresivní terapii
HK1009755B (en)	2003-10-24	Combination therapy for treatment of psychoses
EP1256345A1 (en)	2002-11-13	Combination therapy for treatment of psychoses
NO323579B1 (no)	2007-06-11	Anvendelse av olanzapin for fremstilling av et legemiddel for behandling av ekstrem aggresjon
WO2005013961A1 (en)	2005-02-17	Combination therapy for treatment of cognitive disorders or psychoses
MXPA00011354A (en)	2001-07-31	Combination therapy for treatment of bipolar disorders
MXPA00011353A (es)	2001-07-31	Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria

Legal Events

Date	Code	Title	Description
2017-10-09	MK1K	Patent expired